MRNA
Moderna
October 9, 2026 · intraday
- Rarity
- 1.16
- Peak move
- +14.09%
- Float cap
- $71.1B
Moderna is a biotechnology company that develops messenger RNA (mRNA) medicines, selling its COVID-19 vaccines Spikevax and mNEXSPIKE, plus the RSV vaccine mRESVIA, to wholesalers, distributors, retailers, governments and international organizations. It also runs late-stage programs in seasonal flu, combination flu-COVID and norovirus vaccines, personalized cancer therapies with Merck, and rare disease treatments. Founded in 2010 and based in Cambridge, Massachusetts, it sells mainly in the United States, Europe and other global markets.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
12 events · 0 from SEC or newswire · 0 timed with the movepublic_healthRussia's RosPotrebNadzor stated on Oct. 8 that reports of a second unknown-cause pneumonia case among contacts of a researcher who died at the Irkutsk anti-plague institute were untrue, with about 5,000 lab tests finding no dangerous pathogens.
- Key event
policy_changeA New York Times report detailed a new NIH public-private partnership, including the Foundation for the NIH, drugmakers, biotech firms and patient groups, to accelerate personalized cancer vaccine development, expected to launch in December and initially targeting pancreatic, liver and colorectal cancers and some childhood tumors.
- Key event
analyst_ratingBofA Securities raised its price target on Moderna to $200 from $170 while maintaining a Neutral rating.
insider_saleModerna executive James M. Mock sold 704 shares on October 5, 2026, disclosed in an insider transaction filing on October 7.
major_contractTempus AI announced an expanded multi-year collaboration with Moderna and Merck to support potential commercialization of intismeran autogene (V940/mRNA-4157), managing tumor tissue and blood sample collection and providing next-generation sequencing, with financial terms undisclosed.
analyst_ratingMorgan Stanley raised its price target on Moderna to $95 from $89 while maintaining an Equal-Weight rating.
public_healthWHO spokesperson Christian Lindmeier said tests on contacts of a researcher who died at Russia's Irkutsk Anti-Plague Research Institute detected no plague bacteria and no contacts showed symptoms, assessing regional epidemic risk as medium-to-low and European risk as very low, on Oct. 7, 2026.
index_rebalanceModerna was added to the Nasdaq-100 Index before the market open on Oct. 9, 2026, replacing Warner Bros. Discovery, requiring more than 200 index-tracking products with over $800 billion in assets to adjust holdings.
ceo_cfo_departureModerna Chief Technology and Quality Officer Jerh Collins decided to retire, stepping down as the company created a new COO role under Juan Andres.
investor_dayModerna said it will present Phase 3 data for intismeran autogene in completely resected stage IIB-IV melanoma at a Presidential Symposium on Oct. 24, 2026, and will host an investor webcast the same day, with three abstracts accepted for ESMO 2026.
analyst_ratingCiti analyst Geoff Meacham downgraded Moderna to Sell from Neutral, raising his target to $80 from $60, saying expectations for the cancer pipeline have run too high.
executive_appointmentModerna appointed former executive Juan Andres as Chief Operating Officer effective Oct. 5, 2026, a newly created role overseeing global manufacturing and operations and reporting to CEO Stephane Bancel, with an initial base salary of $800,000 and $5 million in stock.